| Enhanced solubility and stability of anticancer agents |
| Co-delivery of two or more anticancer agents |
| Long circulation half-life |
| Passive targeting enhancing permeation and retention effects |
| Ability to navigate the tumour microenvironment and prevent multidrug resistance |
| Active targeting increasing cellular uptake and internalization |
| Low systemic/off-target toxicity |
| Controlled drug release |
| More specific and sensitive imaging |
| Better imaging contrast enhancement |
| Safer MRI contrast agents |
| Multimodality imaging |
| Theranostic potential (ability to image and treat simultaneously) |
